Skip to main content

MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting


Planegg/Munich, Germany, November 2, 2023 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that data from the Phase 3 MANIFEST-2 trial of pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis will be presented during an oral presentation on Sunday, December 10, at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The conference is being held in San Diego, California, from December 9 to 12, 2023.

ASH 2023 Accepted Abstracts
Abstracts listed below include both MorphoSys-led and partner abstracts.

Abstract Title
Abstract Number Date/Time
Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study
#628 Sunday, December 10, 4:30 p.m. – 6:00 p.m. PST / Monday, December 11, 1:30 a.m. – 3:00 a.m. CET
Presentation Time: 5:15 p.m. PST
Assessment of Minimal Clinically Important Difference in Patient-Reported Myelofibrosis-Associated Symptoms Using an Anchor-Based Analysis Based on MANIFEST Arm 3 Data
#3195 Sunday, December 10,
6:00 p.m. – 8:00 p.m. PST / Monday, December 11, 3:00 a.m. – 5:00 a.m. CET

Press Release